2ak4 › Citations

T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide.

Tynan FE, Burrows SR, Buckle AM, Clements CS, Borg NA, Miles JJ, Beddoe T, Whisstock JC, Wilce MC, Silins SL, Burrows JM, Kjer-Nielsen L, Kostenko L, Purcell AW, McCluskey J, Rossjohn J
Nat Immunol 6 1114-22 (2005)
Cited: 214 times
EuropePMC logo PMID: 16186824

Abstract

Unusually long major histocompatibility complex (MHC) class I-restricted epitopes are important in immunity, but their 'bulged' conformation represents a potential obstacle to alphabeta T cell receptor (TCR)-MHC class I docking. To elucidate how such recognition is achieved while still preserving MHC restriction, we have determined here the structure of a TCR in complex with HLA-B(*)3508 presenting a peptide 13 amino acids in length. This complex was atypical of TCR-peptide-MHC class I interactions, being dominated at the interface by peptide-mediated interactions. The TCR assumed two distinct orientations, swiveling on top of the centrally bulged, rigid peptide such that only limited contacts were made with MHC class I. Although the TCR-peptide recognition resembled an antibody-antigen interaction, the TCR-MHC class I contacts defined a minimal 'generic footprint' of MHC-restriction. Thus our findings simultaneously demonstrate the considerable adaptability of the TCR and the 'shape' of MHC restriction.

Reviews - 2ak4 mentioned but not cited (9)

  1. TCR Signaling: Mechanisms of Initiation and Propagation. Courtney AH, Lo WL, Weiss A. Trends Biochem Sci 43 108-123 (2018)
  2. Evolutionarily conserved amino acids that control TCR-MHC interaction. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. Annu Rev Immunol 26 171-203 (2008)
  3. The structural basis of αβ T-lineage immune recognition: TCR docking topologies, mechanotransduction, and co-receptor function. Wang JH, Reinherz EL. Immunol Rev 250 102-119 (2012)
  4. TCR Recognition of Peptide-MHC-I: Rule Makers and Breakers. Szeto C, Lobos CA, Nguyen AT, Gras S. Int J Mol Sci 22 E68 (2020)
  5. Emerging Concepts in TCR Specificity: Rationalizing and (Maybe) Predicting Outcomes. Singh NK, Riley TP, Baker SCB, Borrman T, Weng Z, Baker BM. J Immunol 199 2203-2213 (2017)
  6. Coevolution of T-cell receptors with MHC and non-MHC ligands. Castro CD, Luoma AM, Adams EJ. Immunol Rev 267 30-55 (2015)
  7. The versatility of the αβ T-cell antigen receptor. Bhati M, Cole DK, McCluskey J, Sewell AK, Rossjohn J. Protein Sci 23 260-272 (2014)
  8. The perception and response of T cells to a changing environment are based on the law of initial value. Huseby ES, Teixeiro E. Sci Signal 15 eabj9842 (2022)
  9. Unconventional Peptide Presentation by Classical MHC Class I and Implications for T and NK Cell Activation. Zajonc DM. Int J Mol Sci 21 E7561 (2020)

Articles - 2ak4 mentioned but not cited (22)



Reviews citing this publication (50)

  1. How TCRs bind MHCs, peptides, and coreceptors. Rudolph MG, Stanfield RL, Wilson IA. Annu Rev Immunol 24 419-466 (2006)
  2. T cell antigen receptor recognition of antigen-presenting molecules. Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. Annu Rev Immunol 33 169-200 (2015)
  3. More than one reason to rethink the use of peptides in vaccine design. Purcell AW, McCluskey J, Rossjohn J. Nat Rev Drug Discov 6 404-414 (2007)
  4. Why must T cells be cross-reactive? Sewell AK. Nat Rev Immunol 12 669-677 (2012)
  5. Mechanisms for T cell receptor triggering. van der Merwe PA, Dushek O. Nat Rev Immunol 11 47-55 (2011)
  6. Structural determinants of T-cell receptor bias in immunity. Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Nat Rev Immunol 6 883-894 (2006)
  7. The molecular basis for public T-cell responses? Venturi V, Price DA, Douek DC, Davenport MP. Nat Rev Immunol 8 231-238 (2008)
  8. The molecular basis of TCR germline bias for MHC is surprisingly simple. Garcia KC, Adams JJ, Feng D, Ely LK. Nat Immunol 10 143-147 (2009)
  9. Bias in the αβ T-cell repertoire: implications for disease pathogenesis and vaccination. Miles JJ, Douek DC, Price DA. Immunol Cell Biol 89 375-387 (2011)
  10. Specificity of T-cell alloreactivity. Felix NJ, Allen PM. Nat Rev Immunol 7 942-953 (2007)
  11. Understanding the drivers of MHC restriction of T cell receptors. La Gruta NL, Gras S, Daley SR, Thomas PG, Rossjohn J. Nat Rev Immunol 18 467-478 (2018)
  12. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J. Annu Rev Pharmacol Toxicol 52 401-431 (2012)
  13. Structural and biophysical determinants of αβ T-cell antigen recognition. Bridgeman JS, Sewell AK, Miles JJ, Price DA, Cole DK. Immunology 135 9-18 (2012)
  14. The fidelity, occasional promiscuity, and versatility of T cell receptor recognition. Godfrey DI, Rossjohn J, McCluskey J. Immunity 28 304-314 (2008)
  15. Identification of T-cell epitopes for cancer immunotherapy. Kessler JH, Melief CJ. Leukemia 21 1859-1874 (2007)
  16. Antigen recognition by CD1d-restricted NKT T cell receptors. Godfrey DI, Pellicci DG, Patel O, Kjer-Nielsen L, McCluskey J, Rossjohn J. Semin Immunol 22 61-67 (2010)
  17. T-cell receptor bias and immunity. Gras S, Kjer-Nielsen L, Burrows SR, McCluskey J, Rossjohn J. Curr Opin Immunol 20 119-125 (2008)
  18. Alloreactivity from human viral specific memory T-cells. D'Orsogna LJ, Roelen DL, Doxiadis II, Claas FH. Transpl Immunol 23 149-155 (2010)
  19. Coping with loss of perfection in the MHC class I peptide repertoire. Blanchard N, Shastri N. Curr Opin Immunol 20 82-88 (2008)
  20. DEPTOR at the Nexus of Cancer, Metabolism, and Immunity. Caron A, Briscoe DM, Richard D, Laplante M. Physiol Rev 98 1765-1803 (2018)
  21. Understanding the Pathogenesis of Spondyloarthritis. Sharip A, Kunz J. Biomolecules 10 E1461 (2020)
  22. A structural perspective on MHC class Ib molecules in adaptive immunity. Sullivan LC, Hoare HL, McCluskey J, Rossjohn J, Brooks AG. Trends Immunol 27 413-420 (2006)
  23. Structural studies on HLA-G: implications for ligand and receptor binding. Clements CS, Kjer-Nielsen L, McCluskey J, Rossjohn J. Hum Immunol 68 220-226 (2007)
  24. Recognition of self-peptide-MHC complexes by autoimmune T-cell receptors. Deng L, Mariuzza RA. Trends Biochem Sci 32 500-508 (2007)
  25. T-cell allorecognition: a case of mistaken identity or déjà vu? Archbold JK, Macdonald WA, Burrows SR, Rossjohn J, McCluskey J. Trends Immunol 29 220-226 (2008)
  26. The structural bases of direct T-cell allorecognition: implications for T-cell-mediated transplant rejection. Gras S, Kjer-Nielsen L, Chen Z, Rossjohn J, McCluskey J. Immunol Cell Biol 89 388-395 (2011)
  27. Tracking phenotypically and functionally distinct T cell subsets via T cell repertoire diversity. Kedzierska K, La Gruta NL, Stambas J, Turner SJ, Doherty PC. Mol Immunol 45 607-618 (2008)
  28. Peptide and Peptide-Dependent Motions in MHC Proteins: Immunological Implications and Biophysical Underpinnings. Ayres CM, Corcelli SA, Baker BM. Front Immunol 8 935 (2017)
  29. Specificity on a knife-edge: the alphabeta T cell receptor. Clements CS, Dunstone MA, Macdonald WA, McCluskey J, Rossjohn J. Curr Opin Struct Biol 16 787-795 (2006)
  30. Improving T cell responses to modified peptides in tumor vaccines. Buhrman JD, Slansky JE. Immunol Res 55 34-47 (2013)
  31. Understanding the complexity and malleability of T-cell recognition. Miles JJ, McCluskey J, Rossjohn J, Gras S. Immunol Cell Biol 93 433-441 (2015)
  32. Understanding the structural dynamics of TCR-pMHC complex interactions. Kass I, Buckle AM, Borg NA. Trends Immunol 35 604-612 (2014)
  33. What guides MHC-restricted TCR recognition? Mazza C, Malissen B. Semin Immunol 19 225-235 (2007)
  34. TCR-MHC docking orientation: natural selection, or thymic selection? Collins EJ, Riddle DS. Immunol Res 41 267-294 (2008)
  35. T-cells behaving badly: structural insights into alloreactivity and autoimmunity. Ely LK, Burrows SR, Purcell AW, Rossjohn J, McCluskey J. Curr Opin Immunol 20 575-580 (2008)
  36. Mechanisms controlling granule-mediated cytolytic activity of cytotoxic T lymphocytes. Anikeeva N, Sykulev Y. Immunol Res 51 183-194 (2011)
  37. Recognition of self and altered self by T cells in autoimmunity and allergy. Yin L, Dai S, Clayton G, Gao W, Wang Y, Kappler J, Marrack P. Protein Cell 4 8-16 (2013)
  38. Targeting the MHC Ligandome by Use of TCR-Like Antibodies. Høydahl LS, Frick R, Sandlie I, Løset GÅ. Antibodies (Basel) 8 E32 (2019)
  39. Identifying neoantigens for use in immunotherapy. Hutchison S, Pritchard AL. Mamm Genome 29 714-730 (2018)
  40. Structural immunology and crystallography help immunologists see the immune system in action: how T and NK cells touch their ligands. Chen Y, Shi Y, Cheng H, An YQ, Gao GF. IUBMB Life 61 579-590 (2009)
  41. T cell allorecognition and MHC restriction--A case of Jekyll and Hyde? Archbold JK, Ely LK, Kjer-Nielsen L, Burrows SR, Rossjohn J, McCluskey J, Macdonald WA. Mol Immunol 45 583-598 (2008)
  42. Mucosal-associated invariant T cell receptor recognition of small molecules presented by MR1. Awad W, Le Nours J, Kjer-Nielsen L, McCluskey J, Rossjohn J. Immunol Cell Biol 96 588-597 (2018)
  43. Integrating Experiment and Theory to Understand TCR-pMHC Dynamics. Buckle AM, Borg NA. Front Immunol 9 2898 (2018)
  44. Minor histocompatibility antigens: presentation principles, recognition logic and the potential for a healing hand. Spencer CT, Gilchuk P, Dragovic SM, Joyce S. Curr Opin Organ Transplant 15 512-525 (2010)
  45. Predisposed αβ T cell antigen receptor recognition of MHC and MHC-I like molecules? Eckle SB, Turner SJ, Rossjohn J, McCluskey J. Curr Opin Immunol 25 653-659 (2013)
  46. Molecular mimicry and cancer vaccine development. Tagliamonte M, Cavalluzzo B, Mauriello A, Ragone C, Buonaguro FM, Tornesello ML, Buonaguro L. Mol Cancer 22 75 (2023)
  47. Molecular pathways for antigenic peptide generation by ER aminopeptidase 1. Mpakali A, Maben Z, Stern LJ, Stratikos E. Mol Immunol 113 50-57 (2019)
  48. αβ T-cell receptor bias in disease and therapy (Review). Wang CY, Yu PF, He XB, Fang YX, Cheng WY, Jing ZZ. Int J Oncol 48 2247-2256 (2016)
  49. An old Twist in HLA-A: CDR3α Hook up at an R65-joint. Murray JS. Front Immunol 6 268 (2015)
  50. Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement. Hopkins JR, MacLachlan BJ, Harper S, Sewell AK, Cole DK. Discov Immunol 1 kyac001 (2022)

Articles citing this publication (133)



Quick links